Navigation Links
Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
Date:1/16/2008

ation ("FDA") to conduct a Phase I clinical study with L-DOS47 in lung adenocarcinoma patients.

About KBI BioPharma

KBI Biopharma Inc. is a contract biopharmaceutical development organization offering a full range of preformulation/formulation development, analytical method development and validation, full process development and clinical manufacturing (for both mammalian and microbial programs). Services are carried out in state-of-the-art laboratories housed in Durham, North Carolina. More information can be obtained from http://www.kbibiopharma.com.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP" and quoted on the Frankfurt, Berlin, Munich and Stuttgart Stock Exchanges under the same symbol.

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release. Helix has relied solely on KBI Biopharma for the information about KBI Biopharma provided in this News Release and Helix disclaims any liability with respect to such information. Helix disclaims responsibility for information contained in any linked or referenced website, and such links and references do not constitute an endorsement by Helix of those or any other website. This News Release contains forward-looking statements and information regarding production of L-DOS47, a planned Phase I clinical study, and products under development, which statements can be identified by the words "will", "potential", "is thought", "is believed", "intends", and "developing". A
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Immunovaccine Inc. (“Immunovaccine” or the “Company”) ... press release disseminated this morning by PR Web, and ... press release states that Immunovaccine has entered into a ... release did not originate from Immunovaccine and there is ... release. Please note that all official statements by ...
(Date:2/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has ... Trypsin" report to their offering. , ... comprehensive data on Trypsin globally and regionally ( Europe ... America , Latin America etc.). ... This report focuses on three primary areas; manufacture ...
(Date:2/27/2015)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... announced that it will be presenting at CALBIO 2015 ... nd at 3pm PST. Patrick Lucy, chief business officer ... current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and The ...
(Date:2/27/2015)... BOSTON , Feb. 27, 2015   PureTech ... identifying, inventing and commercializing disruptive products and technologies in ... Christopher Viehbacher , former CEO and Member of the ... Directors.  "It,s has been a pleasure ... very excited that we will be working together more ...
Breaking Biology Technology:Immunovaccine Disclaims Hoax Press Release 2Global Market Report of Trypsin 2014-2018 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4
... 20 L.J. Star , Inc., ... indicators, announced that it has a suite of solutions for the special ... , , ... connect and visually monitor fluid flows, and thereby help maintain strict control ...
... WORCESTER, Mass. An algorithm developed by Ki H. ... at Worcester Polytechnic Institute (WPI), in partnership with Snehraj ... a new heart monitoring system to detect incidents of ... arrhythmia, far more accurately than previous methods. The algorithm, ...
... Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be presenting at the Citi Investment ... 26, 2010 at 3:00 p.m. ET / 12:00 p.m. ... Pharmaceuticals, will provide a corporate overview. , ... The presentation will be webcast live through the "Investors" section of Amylin,s corporate ...
Cached Biology Technology:L.J. Star Announces Stainless Sanitary Fittings, Sight Glasses and Sight Flow Indicators for the Special Demands of the Pharmaceutical Industry 2L.J. Star Announces Stainless Sanitary Fittings, Sight Glasses and Sight Flow Indicators for the Special Demands of the Pharmaceutical Industry 3L.J. Star Announces Stainless Sanitary Fittings, Sight Glasses and Sight Flow Indicators for the Special Demands of the Pharmaceutical Industry 4Detection of potentially deadly atrial fibrillation dramatically improved by new algorithm 2Detection of potentially deadly atrial fibrillation dramatically improved by new algorithm 3Amylin Pharmaceuticals to Present at the 2010 Citi Investment Research Global Healthcare Conference 2
(Date:2/24/2015)... This report analyzes the worldwide markets for Face and ... and Voice Biometrics. The report provides separate comprehensive analytics for the ... Europe , Asia-Pacific , ... and Latin America . Annual estimates and forecasts ... historic analysis is provided for these markets. Market data and analytics ...
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/11/2015)... According to a ... Product (Cards and Readers, Biometrics, Controllers, Management Software), ... Healthcare, Education) and By Geography - Global Forecast and Analysis to ... Control Market is expected to reach $10.4 ... of 10.6% between 2014 and 2020. ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... made great strides in identifying genes that lead to ... result in a continuum of social deficits, communication difficulties ... how exactly these genetic risk factors impact the brain,s ... can be developed. This led researchers ...
... ice in the Arctic melting to record lows in ... to their environment. Yet some crustaceans, previously thought to ... ice, were recently discovered to migrate deep underwater and ... disappears. "Our findings provide a basic new understanding ...
... TUCSON, Ariz. (Sept. 13, 2012) -- Shane Snyder, who ... American Water Works Association (AWWA), has been invited to ... of 3,500 at the 2012 International Water Association,s (IWA) ... engineering professor,s presentation will focus not only on his ...
Cached Biology News:Study reveals how common gene mutation affects kids with autism spectrum disorders 2Study reveals how common gene mutation affects kids with autism spectrum disorders 3Surviving without ice 2UA engineering professor Shane Snyder to speak in Korea on international water quality 2
... Modification of Ham's F-12 was developed for ... viral fusion. The modification consists of doubling ... ascorbic acid. The salt concentrations have been ... mg zinc sulfate per liter, which may ...
... whose sequence corresponds to residues 1-18 from rat rab 3D. ... - A - S - A - S - E - ... - D - A - A - D - Q - ... control experiments with the polyclonal antibody that reacts with this product ...
... The EpiTect Bisulfite Kit enables complete ... in less than 6 hours. The ... protection against DNA degradation and a ... guarantee fast and reliable results for ...
... RNA sequences from high throughput synthesis are new ... LC Sciences. These products provide a large number ... sequences delivered in a microtube as a mixture ... verified RNA sequence. This is a custom product ...
Biology Products: